Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

被引：0
|
作者：
Leslie, K. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sill, M. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Darcy, K. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Baron, A. T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wilken, J. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Godwin, A. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Cook, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, J. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Maihle, N. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
[2] Univ Iowa, Albuquerque, NM USA
[3] Gynecol Oncol Grp, Stat Off, Buffalo, NY USA
[4] Univ Kentucky, Lexington, KY USA
[5] Yale Univ, New Haven, CT USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Indiana Univ, Bloomington, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16542
引用
收藏
页数：2
相关论文
共 50 条
  • [11] A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Bender, David
    Sill, Michael W.
    Lankes, Heather A.
    Reyes, Henry D.
    Darus, Christopher J.
    Delmore, James E.
    Rotmensch, Jacob
    Gray, Heidi J.
    Mannel, Robert S.
    Schilder, Jeanne M.
    Hunter, Mark I.
    McCourt, Carolyn K.
    Samuelson, Megan I.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 507 - 512
  • [12] A phase II trial of brivanib in recurrent or persistent enclometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Powell, Matthew A.
    Sill, Michael W.
    Goodfellow, Paul J.
    Benbrook, Doris M.
    Lankes, Heather A.
    Leslie, Kimberly K.
    Jeske, Yvette
    Mannel, Robert S.
    Spillman, Monique A.
    Lee, Paula S.
    Hoffman, James S.
    McMeekin, D. Scott
    Pollock, Pamela M.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (01) : 38 - 43
  • [13] A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study
    Aghajanian, C.
    Sill, M. W.
    Darcy, K.
    Greer, B.
    McMeekin, D. S.
    Rose, P. G.
    Rotmensch, J.
    Barnes, M. N.
    Hanjani, P.
    Leslie, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [14] Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group
    Moore, DH
    Blessing, JA
    Dunton, C
    Buller, RE
    Reid, GC
    GYNECOLOGIC ONCOLOGY, 1999, 75 (03) : 473 - 475
  • [15] Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
    Alvarez, Edwin A.
    Brady, William E.
    Walker, Joan L.
    Rotmensch, Jacob
    Zhou, Xun C.
    Kendrick, James E.
    Yamada, S. Diane
    Schilder, Jeanne M.
    Cohn, David E.
    Harrison, Charles R.
    Moore, Kathleen N.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 22 - 27
  • [16] Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
    Alvarez, E.
    Brady, W.
    Walker, J.
    Rotmensch, J.
    Zhou, X.
    Kendrick, J.
    Yamada, S.
    Aghajanian, C.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S17 - S17
  • [17] A Gynecologic Oncology Group phase II trial of the protein kinase C-β inhibitor enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies
    Usha, L.
    Sill, M.
    Darcy, K.
    Benbrook, D.
    Hurteau, J.
    Michelin, D.
    Mannel, R.
    Hanjani, P.
    De Geest, K.
    Godwin, A.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S16 - S16
  • [18] A phase II trial of amonafide in patients with endometrial cancer - A gynecologic oncology group study
    Asbury, R
    Blessing, JA
    Reid, GC
    McGuire, WP
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (04): : 406 - 407
  • [19] A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Dizon, Don S.
    Sill, Michael W.
    Schilder, Jeanne M.
    McGonigle, Kathryn F.
    Rahman, Zia
    Miller, David S.
    Mutch, David G.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (03) : 441 - 445
  • [20] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
    Burger, Robert A.
    Sill, Michael W.
    Monk, Bradley J.
    Greer, Benjamin E.
    Sorosky, Joel I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
12345